Most Read Articles
06 Dec 2018
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.

Fostemsavir improves virologic efficacy, immunologic response in HIV-1

Audrey Abella
07 Aug 2018

The use of the investigational first-in-class attachment inhibitor fostemsavir led to improved baseline viral and CD4+ T-cell counts in patients with HIV-1 infection who had limited treatment options and were failing their current antiretroviral regimen, according to the subgroup analysis results of the BRIGHTE* study presented at AIDS 2018.

Researchers evaluated the randomized cohort of the study population comprising 272 heavily treatment-experienced participants (67 percent treated for >15 years, 75 percent exposed to ≥5 antiretroviral regimens, median age 48 years, 74 percent male) with confirmed viral load of HIV-1 RNA ≥400 copies/mL who were unable to establish a viable antiretroviral background regimen. Participants received either fostemsavir 600 mg twice/day or placebo (n=203 and 69, respectively) for 8 days on top of their failing regimen. After which, all participants received open-label fostemsavir plus optimized background therapy until week 24. [AIDS 2018, abstract THPEB045]

After the first week of treatment, fostemsavir demonstrated superior efficacy over placebo, generating a clinically significant reduction in viral load (adjusted mean log10 HIV-1 RNA, -0.79 vs -0.17 log10 copies/mL, treatment difference, -0.63, 95 percent confidence interval, -0.81 to -0.44; p<0.0001), which was similar across demographic (ie, age, gender, race, geographic region) and baseline disease subgroups (viral load and CD4+ count).

Fostemsavir use also resulted in a median decline in HIV-1 RNA of 1 log10 copies/mL among patients with baseline HIV-1 RNA >1,000 copies/mL at day 8.

Achieving a meaningful reduction in viral load in a span of one week is a promising outcome, noted the researchers, considering the participants’ limited treatment options and drug resistance.

At week 24, more than half of fostemsavir recipients (54 percent) achieved virologic suppression (HIV-1 RNA <40 copies/mL), with similar virologic response rates across all subgroups. However, lower response rates were observed among those who had a high baseline viral load and low baseline CD4+ count (38 percent with ≥100,000 copies/mL and 37 percent with <50 cells/µL, respectively) as opposed to those with low baseline viral load and high baseline CD4+ count (60 percent with <100,000 copies/mL and 63 percent with 50 cells/µL, respectively).

Regarding CD4+ T-cell count, mean increase was similar across all subgroups at week 24, ranging from 74 to 119 cells/µL (mean, 90 cells/µL), except for those with a baseline CD4+ T-cell count of <1,000 cells/µL (mean, 22 cells/µL).

Participants with a low baseline CD4+ count (<20 cells/µL) had an average increase of 97 cells/µL which, according to the researchers, is comparable in magnitude to the mean change in all other baseline CD4+ categories.

Establishing a regimen that could reduce viral load to undetectable levels and improve CD4+ count is important, as high baseline viral load and low CD4+ count increase the risk of developing comorbidities and HIV progression and transmission. [CD4, viral load, and other tests, www.aidsmap.com, accessed 6 August 2018]

These findings underscore the potential of fostemsavir in addressing the issue of antiviral resistance, which remains an unmet need in heavily treatment-experienced patients with HIV. [J Pharm Sci 2013;102:1742-1751; Infect Disord Drug Targets 2011;11:124-133]

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Dec 2018
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.